The following is a summary of “Computed tomography derived predictors of left ventricular obstruction after TAVR,” published ...

Barclays analyst initiates Positive coverage on Anteris Technologies, forecasting a 4%-5% U.S. TAVR market share for DurAVR ...

Nat Clin Pract Cardiovasc Med. 2008;5(12):764-765. We believe that strategies to avoid or reduce the severity of PPM should be individualized and take into account multiple variables, such as ...

North America to Lead Revenue While Asia Pacific Emerges as the Fastest-Growing Region, Driven by Rising Cardiovascular Cases ...

Lipoprotein(a) doesn’t influence calcification or outcomes in TAVR, shifting focus to other AS progression factors.

THE SOLVE-TAVI trial demonstrated that both valve type and anaesthesia strategy yielded comparable long-term outcomes in ...

Raipur: The cardio surgery department of state-run Dr Bhimrao Ambedkar Memorial Hospital successfully performed a challenging open heart surgery on a .

Barclays analyst Matt Miksic initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $22 price target The timing for ...

US-based Lantheus Holdings becomes largest shareholder in Radiopharm Theranostics after US$5 million private placement.

Cantor Fitzgerald analyst Ross Osborn initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $9 price target Anteris ...